In a subset of patients diagnosed with non-small cell lung cancer (NSCLC), immunotherapy paradoxically exacerbates tumor growth and significantly shortens survival. Currently there are no clinically validated biomarkers that can identify patients at risk of this paradoxical response called “hyperprogression.”
Using artificial intelligence (AI) analysis of simple tissue scans, researchers at Case Western University claim they have discovered biomarkers that could tell which lung cancer patients might get worse from immunotherapy.
